Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.

PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 2, 2022

Primary Completion Date

March 2, 2026

Study Completion Date

March 2, 2026

Conditions
Advanced Chronic Liver DiseasePortal HypertensionHepatocellular Carcinoma
Interventions
DRUG

Zinc Acexamate

"The experimental group will receive ACZ at a daily dose of 600 mg, equivalent to 100mg of elemental zinc (one hard gelatin capsule of 300 mg of ACZ twice a day). Treatment will be stopped when the patient presents any of the events that define the main endpoint of the study.~The control group will receive twice a day orally hard gelatin capsules, identical to those of ACZ, in color, weight and nature, but containing an inert preparation (isomaltose)."

Trial Locations (1)

08035

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
collaborator

Hospital General Universitario Gregorio Marañon

OTHER

collaborator

Hospital Vall d'Hebron

OTHER

collaborator

Hospital Universitario Puerta del Hierro

UNKNOWN

collaborator

Hospital Clinic of Barcelona

OTHER

collaborator

Hospital Universitario Central de Asturias

OTHER

collaborator

Complejo Hospitalario de Toledo

OTHER

collaborator

Germans Trias i Pujol Hospital

OTHER

collaborator

Hospital Universitario Marqués de Valdecilla

OTHER

collaborator

Hospital Miguel Servet

OTHER

collaborator

Parc Taulí Hospital Universitari

OTHER

collaborator

Hospital de la Santa creu i Sant Pau - Barcelona

OTHER

collaborator

Hospital Universitari de Bellvitge

OTHER

collaborator

Hospital del Mar

OTHER

collaborator

University Hospital of Girona Dr. Josep Trueta

NETWORK

lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER